Examiner Cite

No

Initial*

5

Patent Number

Kind

Code1

Issue Date

If you wish to add additional Foreign Patent Document citation information please click the Add button

publisher, city and/or country where published.

PTO/SB/08a (01-10)
Approved for use through 07/31/2012 OMB 0861-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless if contains a valid OMS control number

Remove

Add Remove

Тs

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

| | Application Number | | 10591946 | |
|---|----------------------|-------|------------|--|
| | Filing Date | | 2006-11-30 | |
| | First Named Inventor | OBEF | RLE . | |
| STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99) | Art Unit | | 3656 | |
| | Examiner Name | Danie | D. YABUT | |
| | Attorney Docket Numb | er | 27634U | |

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

| | 1 | | | | | | | | | |
|--|---------------------------------|---|------------------------------|-----------------|---------------------------|---|---|--|---|----|
| If you wisi | h to ad | d additional U.S. Pate | nt citatio | n inform | ation pl | l lease click the | Add button. | _ | Add | _ |
| U.S.PATENT APPLICATION PUBLICATIONS Remove | | | | | | | | | | |
| Examiner Initial* | Cite N | Publication Number | Kind Code ¹ | Publica Date | ation | Name of Patentee or Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | | | | | | | | | |
| If you wish to add additional U.S. Published Application citation information please click the Add button. Add | | | | | | | | | | |
| | FOREIGN PATENT DOCUMENTS Remove | | | | | | | | | |
| Examiner Initial* | | Foreign Document Number ³ | Country Code ² | | Kind Code ⁴ | | Name of Patente Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | Ts |
| | 1 | 5-50211 | JP | | U | 1993-07-02 | | | | П |

NON-PATENT LITERATURE DOCUMENTS

Remove
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Examiner Cite

Initials* No

| INFORMATION DISCLOSURE | Filing Date | 2006-11-30 | Filing Date | 2006-11

| 1 | |
|---|--|

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petert Documents at time USETO.GGU or MREP 991.94. * Enter office that issued the document, by the to-relater own (MPC)
Standard 57.3. * "For uppersee petert of counters, the orbidates of the parent of the repart or present present or the parent of the parent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10591946 | | |
|------------------------|-------|------------|--|--|
| Filing Date | | 2006-11-30 | | |
| First Named Inventor | OBEF | BERLE | | |
| Art Unit | | 3656 | | |
| Examiner Name | Danie | D. YABUT | | |
| Attorney Docket Number | | 27634U | | |

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign papel patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/37(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| | • | | | | | | |
|------------|-------------------|---------------------|------------|--|--|--|--|
| Signature | /Jeraid L. Meyer/ | Date (YYYY-MM-DD) | 2011-09-28 | | | | |
| Name/Print | Jerald I Meyer | Registration Number | 41.194 | | | | |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.